Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

CD133: a cancer stem cells marker, is used in colorectal cancers.

Ren F, Sheng WQ, Du X.

World J Gastroenterol. 2013 May 7;19(17):2603-11. doi: 10.3748/wjg.v19.i17.2603. Review.

2.

Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A.

Cancer Invest. 2009 Oct;27(8):844-50. doi: 10.1080/07357900902744502.

PMID:
19626493
3.

Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer.

Hongo K, Kazama S, Sunami E, Tsuno NH, Takahashi K, Nagawa H, Kitayama J.

Med Oncol. 2012 Dec;29(4):2849-57. doi: 10.1007/s12032-012-0161-8. Epub 2012 Jan 14.

4.

Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.

Lu C, Xu F, Gu J, Yuan Y, Zhao G, Yu X, Ge D.

J Thorac Cardiovasc Surg. 2015 Aug;150(2):386-95. doi: 10.1016/j.jtcvs.2015.05.030. Epub 2015 May 16.

PMID:
26092504
5.

Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.

Reggiani Bonetti L, Migaldi M, Caredda E, Boninsegna A, Ponz De Leon M, Di Gregorio C, Barresi V, Scannone D, Danese S, Cittadini A, Sgambato A.

Scand J Gastroenterol. 2012 Oct;47(10):1211-7. Epub 2012 Aug 3.

PMID:
22856425
6.

Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.

Shikina A, Shinto E, Hashiguchi Y, Ueno H, Naito Y, Okamoto K, Kubo T, Fukazawa S, Yamamoto J, Hase K.

Jpn J Clin Oncol. 2014 Jan;44(1):42-8. doi: 10.1093/jjco/hyt168. Epub 2013 Nov 14.

7.

How powerful is CD133 as a cancer stem cell marker in brain tumors?

Cheng JX, Liu BL, Zhang X.

Cancer Treat Rev. 2009 Aug;35(5):403-8. doi: 10.1016/j.ctrv.2009.03.002. Epub 2009 Apr 14. Review.

PMID:
19369008
8.

CD133 expression is correlated with poor prognosis in colorectal cancer.

Kashihara H, Shimada M, Kurita N, Iwata T, Sato H, Kozo Yoshikawa, Higashijima J, Chikakiyo M, Nishi M, Matsumoto N.

Hepatogastroenterology. 2014 Sep;61(134):1563-7.

PMID:
25436343
9.

Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells.

Meng X, Li M, Wang X, Wang Y, Ma D.

Cancer Sci. 2009 Jun;100(6):1040-6. doi: 10.1111/j.1349-7006.2009.01144.x. Epub 2009 Feb 20.

10.

CD133 expression is an independent prognostic marker for low survival in colorectal cancer.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A.

Br J Cancer. 2008 Oct 21;99(8):1285-9. doi: 10.1038/sj.bjc.6604664. Epub 2008 Sep 9.

11.

CD44 is of functional importance for colorectal cancer stem cells.

Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q.

Clin Cancer Res. 2008 Nov 1;14(21):6751-60. doi: 10.1158/1078-0432.CCR-08-1034. Erratum in: Clin Cancer Res. 2008 Dec 1;14(23):7964-7.

12.

AC133 expression associated with poor prognosis in stage II colorectal cancer.

Ying X, Wu J, Meng X, Zuo Y, Xia Q, Chen J, Feng Y, Liu R, Li L, Huang W.

Med Oncol. 2013 Mar;30(1):356. doi: 10.1007/s12032-012-0356-z. Epub 2013 Jan 16.

PMID:
23322518
13.

Subpopulation of colorectal adenocarcinoma cells co-expressing CD133 and cancer stem cells markers of other tumors.

Gisina AM, Lupatov AY, Karalkin PA, Mainovskaya OA, Petrov LO, Sidorov DV, Frank GA, Yarygin KN.

Bull Exp Biol Med. 2012 Apr;152(6):739-42. English, Russian.

PMID:
22803178
14.

Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.

Pitule P, Cedikova M, Daum O, Vojtisek J, Vycital O, Hosek P, Treska V, Hes O, Kralickova M, Liska V.

Biomed Res Int. 2014;2014:432139. doi: 10.1155/2014/432139. Epub 2014 Apr 22.

15.

[The utilization and limitation of CD133 epitopes in lung cancer stem cells research].

Chen Y, Zhong H.

Zhongguo Fei Ai Za Zhi. 2011 Oct;14(10):825-9. doi: 10.3779/j.issn.1009-3419.2011.10.10. Review. Chinese.

16.

The stem cell marker CD133 is highly expressed in sessile serrated adenoma and its borderline variant compared with hyperplastic polyp.

Mohammadi M, Bzorek M, Bonde JH, Nielsen HJ, Holck S.

J Clin Pathol. 2013 May;66(5):403-8. doi: 10.1136/jclinpath-2012-201192. Epub 2013 Feb 22.

PMID:
23436931
17.

Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma.

Zhang Y, Sun B, Zhao X, Liu Z, Wang X, Yao X, Dong X, Chi J.

J Surg Oncol. 2013 Nov;108(6):414-9. doi: 10.1002/jso.23402. Epub 2013 Aug 29.

PMID:
23996537
18.

CD133 is a selective marker of CRC?

Del Rio P, Bonati E, Crafa P, Campanini N, Montana Montana C, Bezer L, Dell'Abate P, Sianesi M.

Minerva Chir. 2013 Feb;68(1):87-95.

PMID:
23584268
19.

Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.

Shimada R, Iinuma H, Akahane T, Horiuchi A, Watanabe T.

Oncol Rep. 2012 Apr;27(4):947-53. doi: 10.3892/or.2012.1649. Epub 2012 Jan 19.

20.

Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.

Yamamoto S, Tanaka K, Takeda K, Akiyama H, Ichikawa Y, Nagashima Y, Endo I.

Ann Surg Oncol. 2014 Jun;21(6):1853-61. doi: 10.1245/s10434-014-3549-1. Epub 2014 Feb 20.

PMID:
24554065
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk